This review summarizes the current pharmacological and non-pharmacological management strategies for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
Consolidates CPVT management options for clinicians; leaves open need for prospective trials to optimize strategies.
Pharmacological and Non- Pharmacological Therapies of Catecholaminergic Polymorphic Ventricular Tachycardia Polymorphic Ventricular Tachycardia (CPVT) is an inherited cardiac channelopathy characterized by exercise related ventricular tachycardia (VT) manifested as syncope and sudden death among young patients with structurally normal hearts. High dose Beta blocker is the mainstay therapy. Recently, flecainide was introduced to treat symptomatic CPVT patients despite beta blockers. Implantable cardioverter defibrillator is recommended for symptomatic patients if optimal medical treatment does not control ventricular arrhythmias. Left cardiac sympathetic denervation should be considered for intractable cases.
No takes yet. Share an insight, caveat, or question.
M Boulos (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: